Aug 21, 2018 7:30am EDT ProMIS Neurosciences Oligomer Selective Antibody Therapeutic for Alzheimer's Disease, PMN310, Shows Potential for Improved Safety Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies in Clinical Development
Aug 07, 2018 7:30am EDT ProMIS Neurosciences Issues Narrated Commentary on Key Learnings from AAIC 2018
Jul 31, 2018 7:30am EDT ProMIS Neurosciences Issues White Paper Entitled 'State of the Art at AAIC 2018'
Jul 10, 2018 7:30am EDT ProMIS Neurosciences to Present Preclinical Data on Alzheimer's Disease Therapeutic Antibody PMN310 at Alzheimer's Association International Conference
Jun 26, 2018 7:30am EDT ProMIS Neurosciences Unique Discovery Platform Generates Potential New Antibody Therapeutics for Neurodegenerative Diseases
Jun 20, 2018 7:30am EDT ProMIS Neurosciences Reminds Shareholders of June 25th Voting Cut-Off for Upcoming Annual General Meeting
Jun 12, 2018 7:30am EDT ProMIS Neurosciences Initiates Manufacturing of PMN310, its Lead Therapeutic Antibody for Treatment of Alzheimer's Disease